Aspira Women's Health Inc. financial data

Symbol
AWH on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
12117 Bee Caves Road Building Three, Suite 100, Austin, Texas
State of incorporation
Delaware
Fiscal year end
December 31
Former names
VERMILLION, INC. (to 6/10/2020), CIPHERGEN BIOSYSTEMS INC (to 8/17/2007)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 106 % -55.1%
Quick Ratio 4.71 % -3.09%
Debt-to-equity -422 % -285%
Return On Equity 788 %
Return On Assets -245 % -74.3%
Operating Margin -206 % +45.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 16.1M shares +57.5%
Common Stock, Shares, Outstanding 12.8M shares +51.4%
Entity Public Float 17.7M USD -64.8%
Common Stock, Value, Issued 13K USD +44.4%
Weighted Average Number of Shares Outstanding, Basic 12.5M shares +49%
Weighted Average Number of Shares Outstanding, Diluted 12.5M shares +49%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 9.15M USD +11.9%
Revenue from Contract with Customer, Excluding Assessed Tax 2.42M USD -2.73%
Research and Development Expense 3.93M USD -23.2%
Selling and Marketing Expense 7.47M USD -33.3%
General and Administrative Expense 11.1M USD -15.1%
Operating Income (Loss) -17.4M USD +28.5%
Nonoperating Income (Expense) 863K USD -56.9%
Net Income (Loss) Attributable to Parent -16M USD +25%
Earnings Per Share, Basic -1.41 USD/shares +45.3%
Earnings Per Share, Diluted -1.41 USD/shares +45.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 962K USD -77.3%
Accounts Receivable, after Allowance for Credit Loss, Current 1.45M USD -11.8%
Inventory, Net 226K USD -16.9%
Other Assets, Current 184K USD
Assets, Current 3.25M USD -52.6%
Property, Plant and Equipment, Net 120K USD -54%
Operating Lease, Right-of-Use Asset 559K USD +63.5%
Other Assets, Noncurrent 31K USD
Assets 3.96M USD -48.7%
Accounts Payable, Current 1.94M USD +81.3%
Employee-related Liabilities, Current 90K USD
Accrued Liabilities, Current 2.86M USD -19.5%
Liabilities, Current 5.46M USD +1.56%
Operating Lease, Liability, Noncurrent 437K USD +91.7%
Liabilities 7.67M USD -7.01%
Retained Earnings (Accumulated Deficit) -526M USD -3.78%
Stockholders' Equity Attributable to Parent -3.71M USD -602%
Liabilities and Equity 3.96M USD -48.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.6M USD +22.3%
Net Cash Provided by (Used in) Financing Activities 5.27M USD
Net Cash Provided by (Used in) Investing Activities -20K USD -150%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 12.8M shares +51.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 818K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 962K USD -78.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 6K USD -66.7%
Deferred Tax Assets, Valuation Allowance 57.2M USD +15.1%
Deferred Tax Assets, Gross 57.3M USD +15.3%
Operating Lease, Liability 614K USD +47.6%
Payments to Acquire Property, Plant, and Equipment 20K USD +150%
Lessee, Operating Lease, Liability, to be Paid 688K USD +48.3%
Property, Plant and Equipment, Gross 1.98M USD -37.7%
Operating Lease, Liability, Current 177K USD -5.85%
Lessee, Operating Lease, Liability, to be Paid, Year Two 223K USD +79.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 229K USD +39.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure -11.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 74K USD +54.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 84K USD +31.3%
Deferred Tax Assets, Operating Loss Carryforwards 52.5M USD +18%
Unrecognized Tax Benefits 10.7M USD +4.82%
Lessee, Operating Lease, Liability, to be Paid, Year Four 52K USD
Operating Lease, Payments 465K USD +9.16%
Additional Paid in Capital 516M USD +1.44%
Depreciation, Depletion and Amortization 29K USD -58.6%
Deferred Tax Assets, Net of Valuation Allowance 123K USD
Share-based Payment Arrangement, Expense 122K USD -75%